Kainova Therapeutics has initiated the European expansion of its DOMISOL Phase I/II clinical trial, marking a key milestone in the global development of DT-7012, a Treg-depleting anti-CCR8 monoclonal antibody. The first patient has been dosed in France, following the trial’s launch in Australia in October 2025. This study aims to evaluate DT-7012 both as a monotherapy and in combination with pembrolizumab, involving multiple leading oncology centers in France, including renowned investigators like Dr. Lauriane Eberst and Professor Antoine Italiano.

The significance of this trial lies in its potential to reshape the tumor microenvironment by targeting regulatory T cells (Tregs), which are known to contribute to immunosuppression in advanced solid tumors. DT-7012 selectively depletes Tregs through its action on CCR8, a receptor predominantly expressed on these cells. The study’s design includes paired tumor biopsies to directly assess Treg depletion, providing critical insights into the drug’s mechanism of action and its ability to restore immune competence in the tumor microenvironment. The primary objectives focus on determining the maximum tolerated dose and assessing the safety of DT-7012, both as a standalone treatment and in combination with pembrolizumab.

The implications for the field are substantial, as the DOMISOL study could redefine therapeutic strategies for patients unresponsive to existing immunotherapies. By demonstrating the efficacy of targeted Treg depletion, Kainova Therapeutics may set a new standard for immuno-oncology treatments, potentially accelerating the development timelines for similar therapies that aim to manipulate the immune landscape in cancer. This approach not only enhances our understanding of Treg biology but also opens avenues for future research focused on GPCR-modulating therapies in oncology.

Source: globenewswire.com